Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Jul 22, 2021
Trial Information
Current as of November 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new genetic testing method called ChromoSeq to see if it can improve the diagnosis and treatment of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to find out if using ChromoSeq alongside standard testing can provide helpful information for doctors treating these conditions. The study is currently looking for adult patients who have been suspected of having AML or MDS and for their treating physicians at Washington University School of Medicine.
To participate, patients must be 18 years or older and be willing to provide informed consent. They should also be undergoing diagnostic testing for AML or MDS. Participating physicians will complete surveys to share their experiences with ChromoSeq. If you or a family member are eligible and choose to participate, you can expect to help researchers understand how well this new test works in real-life situations, which could lead to better care for future patients.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria Patient
- • Patient with a clinical suspicion for a new diagnosis of AML or MDS for whom the diagnostic molecular testing via the hematologic molecular algorithm (HMA) at BJH is requested or planned to be requested.
- • Adult patients 18 years or older.
- • Ability to understand and willingness to sign an IRB approved written informed consent document.
- • Inclusion Criteria Physician
- • Treating physician at Washington University School of Medicine who directs therapy for individuals with hematologic malignancies.
- • Able and willing to complete standardized questionnaires about usability, and stakeholder perceptions of ChromoSeq during the ChromoSeq implementation process.
- • Exclusion Criteria Patient
- • Younger than 18 years of age
- • Exclusion Criteria Physician
- • Does not treat patients at Washington University School of Medicine
About Washington University School Of Medicine
Washington University School of Medicine is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research, education, and patient care. With a strong emphasis on translating scientific discoveries into practical applications, the institution conducts a diverse array of clinical trials aimed at improving treatment outcomes and enhancing the understanding of various medical conditions. Its collaborative environment fosters partnerships between researchers, clinicians, and community stakeholders, ensuring that the trials not only contribute to scientific knowledge but also address the pressing health needs of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Louis, Missouri, United States
Patients applied
Trial Officials
Meagan Jacoby, M.D., Ph.D.
Principal Investigator
Washington University School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials